At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 12 enrolled
Drug / intervention
Drug: PF-07817883drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE DOSE, CROSSOVER STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY OF PF-07817883 FOLLOWING ORAL ADMINISTRATION OF NEW FORMULATIONS RELATIVE TO THE REFERENCE FORMULATION IN HEALTHY ADULT PARTICIPANTS UNDER FASTED CONDITION
In Brief
A Phase 1 clinical trial evaluating Drug: PF-07817883 for Healthy. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The purpose of this study is to estimate the oral bioavailability of 3 new formulations of PF-07817883 (test) relative to reference tablet formulation in healthy adult participants under fasted conditions. The study will also assess the safety and tolerability of test and reference tablet formulations in healthy adult participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesBelgium
Collaborators--
Timeline
Phase 1CompletedFinished
202420252026
First PostedNov 2023
Enrollment StartNov 2023
Primary CompletionJan 2024
TodayJul 2026
First PostedNov 8, 2023
Enrollment StartNov 23, 2023
Primary CompletionJan 12, 2024
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 2.6 years ago
Interventions
Drug: PF-07817883drug
PF-07817883 tablet